Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30191% above fair value
$34.01−0.38 (-1.10%)
Close on Nov 19, 2026Market cap $2.53BP/E –Yield –
Xencor operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Xencor's operating income for the twelve months ending Jun 30, 2026 was -$216.08M. For fiscal 2025 it was -$177.50M. The highest annual figure on record is $44.04M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$177.50M | – |
| FY2024 | Dec 31, 2024 | -$178.41M | – |
| FY2023 | Dec 31, 2023 | -$132.36M | – |
| FY2022 | Dec 31, 2022 | -$82.47M | -288.4% |
| FY2021 | Dec 31, 2021 | $43.77M | – |
| FY2020 | Dec 31, 2020 | -$76.80M | -655.5% |
| FY2019 | Dec 31, 2019 | $13.82M | – |
| FY2018 | Dec 31, 2018 | -$79.37M | – |
| FY2017 | Dec 31, 2017 | -$43.12M | -197.9% |
| FY2016 | Dec 31, 2016 | $44.04M | – |
| FY2015 | Dec 31, 2015 | -$18.34M | – |
| FY2014 | Dec 31, 2014 | -$16.46M | – |
| FY2013 | Dec 31, 2013 | -$10.52M | – |
| FY2012 | Dec 31, 2012 | -$6.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$37.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$77.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$53.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$47.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$43.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$55.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$54.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$60.74M | -329.5% |
| Q4 FY2022 | Dec 31, 2022 | -$42.59M | -146.5% |
| Q3 FY2022 | Sep 30, 2022 | -$38.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.00M | -408.1% |
| Q1 FY2022 | Mar 31, 2022 | $26.47M | – |
| Q4 FY2021 | Dec 31, 2021 | $91.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$41.30M | – |
| Q2 FY2021 | Jun 30, 2021 | $9.09M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.70M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.78M | -111.2% |
| Q4 FY2019 | Dec 31, 2019 | -$30.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.28M | -2292.9% |
| Q2 FY2019 | Jun 30, 2019 | -$19.57M | – |
| Q1 FY2019 | Mar 31, 2019 | $78.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.08M | -495.8% |
| Q3 FY2018 | Sep 30, 2018 | $651.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$28.29M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.65M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.33M | – |
| Q3 FY2017 | Sep 30, 2017 | -$23.58M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.36M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.03M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.26M | – |
See a number that looks wrong?